Copy to clipboard 
The data below is based on reported sales from a subset of public orthopedic companies on a quarterly reporting schedule. These companies account for about two-thirds of the global market. I’m using this group as a proxy to measure quarterly market performance.
Orthopedic Market Data for Second Quarter 2025
Where applicable, company names for the current quarter are linked to a more detailed article containing highlights and segment and regional sales data.
Sales for consolidated half, nine months and full-year results are inclusive of all previously-reported data plus data from companies that have reported in the current quarter.
Segment Sales for Reporting Companies
| Segment | 2Q25 | 2Q24 | $ Chg | % Chg |
|---|---|---|---|---|
| Joint Replacement | $4,445.1 | $4,246.1 | $199.1 | 4.7% |
| Knees | $2,169.6 | $2,100.0 | $69.6 | 3.3% |
| Hips | $1,663.9 | $1,581.0 | $83.0 | 5.2% |
| Extremities | $611.6 | $565.1 | $46.5 | 8.2% |
| Spine | $1,161.4 | $1,029.5 | $131.9 | 12.8% |
| Trauma | $1,953.9 | $1,832.5 | $121.4 | 6.6% |
| Sports Medicine | $1,085.3 | $1,022.8 | $62.5 | 6.1% |
| Orthobiologics | $454.1 | $433.8 | $20.3 | 4.7% |
| Enabling Technology | $247.8 | $223.3 | $24.4 | 10.9% |
| Other | $713.8 | $676.6 | $37.2 | 5.5% |
| Total | $10,061.4 | $9,464.6 | $596.8 | 6.3% |
| Segment | 1H25 | 1H24 | $ Chg | % Chg |
|---|---|---|---|---|
| Joint Replacement | $8,757.3 | $8,425.1 | $332.3 | 3.9% |
| Knees | $4,296.8 | $4,172.2 | $124.6 | 3% |
| Hips | $3,246.1 | $3,120.3 | $125.8 | 4% |
| Extremities | $1,214.4 | $1,132.6 | $81.8 | 7.2% |
| Spine | $2,332.2 | $2,175.6 | $156.6 | 7.2% |
| Trauma | $3,828.4 | $3,582.4 | $246.1 | 6.9% |
| Sports Medicine | $2,085.3 | $2,018.9 | $66.3 | 3.3% |
| Orthobiologics | $860.1 | $824.5 | $35.6 | 4.3% |
| Enabling Technology | $459.1 | $464.2 | ($5.1) | (1.1%) |
| Other | $1,381.1 | $1,349.2 | $31.8 | 2.4% |
| Total | $19,703.6 | $18,839.9 | $863.7 | 4.6% |
Total Orthopedic Sales for Reporting Companies
| Company | 2Q25 | 2Q24 | $ Chg | % Chg |
|---|---|---|---|---|
| Anika Therapeutics | $26.6 | $29.0 | ($2.4) | (8.2%) |
| ATEC | $185.5 | $145.6 | $40.0 | 27.5% |
| Bioventus | $135.0 | $133.6 | $1.3 | 1% |
| BONESUPPORT | $25.9 | $20.0 | $5.9 | 29.4% |
| CONMED | $140.7 | $139.5 | $1.2 | 0.9% |
| J&J MedTech | $2,305.1 | $2,312.0 | ($6.9) | (0.3%) |
| Enovis | $284.1 | $262.0 | $22.2 | 8.5% |
| Globus Medical | $745.3 | $629.7 | $115.7 | 18.4% |
| Orthofix | $203.1 | $198.6 | $4.5 | 2.3% |
| OrthoPediatrics | $52.5 | $45.5 | $7.0 | 15.4% |
| SI-BONE | $48.6 | $40.0 | $8.7 | 21.7% |
| Smith+Nephew | $1,037.9 | $975.6 | $62.3 | 6.4% |
| Stryker | $2,692.7 | $2,441.9 | $250.8 | 10.3% |
| Vericel | $53.5 | $44.1 | $9.3 | 21.1% |
| Total | $10,061.4 | $9,464.6 | $596.8 | 6.3% |
| Company | 1H25 | 1H24 | $ Chg | % Chg |
|---|---|---|---|---|
| Anika Therapeutics | $51.2 | $55.7 | ($4.4) | (8%) |
| ATEC | $354.7 | $284.1 | $70.7 | 24.9% |
| Bioventus | $246.0 | $238.3 | $7.7 | 3.2% |
| BONESUPPORT | $51.7 | $36.8 | $14.9 | 40.5% |
| CONMED | $279.0 | $274.4 | $4.6 | 1.7% |
| J&J MedTech | $4,546.3 | $4,652.4 | ($106.1) | (2.3%) |
| Enovis | $584.8 | $532.7 | $52.1 | 9.8% |
| Globus Medical | $1,343.5 | $1,236.4 | $107.1 | 8.7% |
| Orthofix | $396.8 | $387.2 | $9.5 | 2.5% |
| OrthoPediatrics | $98.0 | $84.2 | $13.8 | 16.4% |
| SI-BONE | $95.9 | $77.8 | $18.1 | 23.2% |
| Smith+Nephew | $2,009.3 | $1,935.8 | $73.4 | 3.8% |
| Stryker | $5,460.4 | $4,972.1 | $488.3 | 9.8% |
| Vericel | $99.8 | $84.3 | $15.4 | 18.3% |
| Total | $19,703.6 | $18,839.9 | $863.7 | 4.6% |
Orthopedic Market Developments for Second Quarter 2025
ATEC Takes More Share in Spine
Surgical revenue and revenue from established territories both grew 29%. Surgeon user base grew 21%. ATEC is the third largest player in the U.S. spine market and is on track for profitability by the end of 2025.
CONMED Makes Inroads with BioBrace
BioBrace drove double-digit growth in the second quarter and is now in clinical use across 52 distinct procedures, including rotator cuff and ACL repairs as well as Achilles and gluteus medius reconstructions.
Challenges Stack up for J&J MedTech
Competitive pressures, the previously announced restructuring program and volume-based procurement in China drove sales declines. The company also faced stiff comparisons vs. 2024.
Orthofix Seeks Leadership Position for Complex Limb Reconstruction
Trauma performance was boosted by the TrueLok Elevate Transverse Bone Transport System, which has completed 200 cases since receiving FDA clearance and CE mark registration earlier this year. The company is focused on being the market leader in complex limb reconstruction.
Smith+Nephew Honing U.S. Knee Offerings
The company’s sustained improvement in joint replacement comes amid a commercial shift and portfolio rationalization for knee replacement implants. The commercial organization is refocusing its efforts on higher-volume accounts. The company also plans to narrow down to two product families, LEGION and JOURNEY.
Stryker Bullish on Orthopedic Market Health
Stryker remains bullish on the market environment despite ongoing trade and geopolitical uncertainty, citing healthy procedure volumes, adoption of robotic-assisted surgery, stable pricing, favorable demographic shifts and ongoing ASC acceleration.
The data below is based on reported sales from a subset of public orthopedic companies on a quarterly reporting schedule. These companies account for about two-thirds of the global market. I’m using this group as a proxy to measure quarterly market performance.
Orthopedic Market Data for Second Quarter 2025
Where applicable, company names...
The data below is based on reported sales from a subset of public orthopedic companies on a quarterly reporting schedule. These companies account for about two-thirds of the global market. I’m using this group as a proxy to measure quarterly market performance.
Orthopedic Market Data for Second Quarter 2025
Where applicable, company names for the current quarter are linked to a more detailed article containing highlights and segment and regional sales data.
Sales for consolidated half, nine months and full-year results are inclusive of all previously-reported data plus data from companies that have reported in the current quarter.
Segment Sales for Reporting Companies
| Segment | 2Q25 | 2Q24 | $ Chg | % Chg |
|---|---|---|---|---|
| Joint Replacement | $4,445.1 | $4,246.1 | $199.1 | 4.7% |
| Knees | $2,169.6 | $2,100.0 | $69.6 | 3.3% |
| Hips | $1,663.9 | $1,581.0 | $83.0 | 5.2% |
| Extremities | $611.6 | $565.1 | $46.5 | 8.2% |
| Spine | $1,161.4 | $1,029.5 | $131.9 | 12.8% |
| Trauma | $1,953.9 | $1,832.5 | $121.4 | 6.6% |
| Sports Medicine | $1,085.3 | $1,022.8 | $62.5 | 6.1% |
| Orthobiologics | $454.1 | $433.8 | $20.3 | 4.7% |
| Enabling Technology | $247.8 | $223.3 | $24.4 | 10.9% |
| Other | $713.8 | $676.6 | $37.2 | 5.5% |
| Total | $10,061.4 | $9,464.6 | $596.8 | 6.3% |
| Segment | 1H25 | 1H24 | $ Chg | % Chg |
|---|---|---|---|---|
| Joint Replacement | $8,757.3 | $8,425.1 | $332.3 | 3.9% |
| Knees | $4,296.8 | $4,172.2 | $124.6 | 3% |
| Hips | $3,246.1 | $3,120.3 | $125.8 | 4% |
| Extremities | $1,214.4 | $1,132.6 | $81.8 | 7.2% |
| Spine | $2,332.2 | $2,175.6 | $156.6 | 7.2% |
| Trauma | $3,828.4 | $3,582.4 | $246.1 | 6.9% |
| Sports Medicine | $2,085.3 | $2,018.9 | $66.3 | 3.3% |
| Orthobiologics | $860.1 | $824.5 | $35.6 | 4.3% |
| Enabling Technology | $459.1 | $464.2 | ($5.1) | (1.1%) |
| Other | $1,381.1 | $1,349.2 | $31.8 | 2.4% |
| Total | $19,703.6 | $18,839.9 | $863.7 | 4.6% |
Total Orthopedic Sales for Reporting Companies
| Company | 2Q25 | 2Q24 | $ Chg | % Chg |
|---|---|---|---|---|
| Anika Therapeutics | $26.6 | $29.0 | ($2.4) | (8.2%) |
| ATEC | $185.5 | $145.6 | $40.0 | 27.5% |
| Bioventus | $135.0 | $133.6 | $1.3 | 1% |
| BONESUPPORT | $25.9 | $20.0 | $5.9 | 29.4% |
| CONMED | $140.7 | $139.5 | $1.2 | 0.9% |
| J&J MedTech | $2,305.1 | $2,312.0 | ($6.9) | (0.3%) |
| Enovis | $284.1 | $262.0 | $22.2 | 8.5% |
| Globus Medical | $745.3 | $629.7 | $115.7 | 18.4% |
| Orthofix | $203.1 | $198.6 | $4.5 | 2.3% |
| OrthoPediatrics | $52.5 | $45.5 | $7.0 | 15.4% |
| SI-BONE | $48.6 | $40.0 | $8.7 | 21.7% |
| Smith+Nephew | $1,037.9 | $975.6 | $62.3 | 6.4% |
| Stryker | $2,692.7 | $2,441.9 | $250.8 | 10.3% |
| Vericel | $53.5 | $44.1 | $9.3 | 21.1% |
| Total | $10,061.4 | $9,464.6 | $596.8 | 6.3% |
| Company | 1H25 | 1H24 | $ Chg | % Chg |
|---|---|---|---|---|
| Anika Therapeutics | $51.2 | $55.7 | ($4.4) | (8%) |
| ATEC | $354.7 | $284.1 | $70.7 | 24.9% |
| Bioventus | $246.0 | $238.3 | $7.7 | 3.2% |
| BONESUPPORT | $51.7 | $36.8 | $14.9 | 40.5% |
| CONMED | $279.0 | $274.4 | $4.6 | 1.7% |
| J&J MedTech | $4,546.3 | $4,652.4 | ($106.1) | (2.3%) |
| Enovis | $584.8 | $532.7 | $52.1 | 9.8% |
| Globus Medical | $1,343.5 | $1,236.4 | $107.1 | 8.7% |
| Orthofix | $396.8 | $387.2 | $9.5 | 2.5% |
| OrthoPediatrics | $98.0 | $84.2 | $13.8 | 16.4% |
| SI-BONE | $95.9 | $77.8 | $18.1 | 23.2% |
| Smith+Nephew | $2,009.3 | $1,935.8 | $73.4 | 3.8% |
| Stryker | $5,460.4 | $4,972.1 | $488.3 | 9.8% |
| Vericel | $99.8 | $84.3 | $15.4 | 18.3% |
| Total | $19,703.6 | $18,839.9 | $863.7 | 4.6% |
Orthopedic Market Developments for Second Quarter 2025
ATEC Takes More Share in Spine
Surgical revenue and revenue from established territories both grew 29%. Surgeon user base grew 21%. ATEC is the third largest player in the U.S. spine market and is on track for profitability by the end of 2025.
CONMED Makes Inroads with BioBrace
BioBrace drove double-digit growth in the second quarter and is now in clinical use across 52 distinct procedures, including rotator cuff and ACL repairs as well as Achilles and gluteus medius reconstructions.
Challenges Stack up for J&J MedTech
Competitive pressures, the previously announced restructuring program and volume-based procurement in China drove sales declines. The company also faced stiff comparisons vs. 2024.
Orthofix Seeks Leadership Position for Complex Limb Reconstruction
Trauma performance was boosted by the TrueLok Elevate Transverse Bone Transport System, which has completed 200 cases since receiving FDA clearance and CE mark registration earlier this year. The company is focused on being the market leader in complex limb reconstruction.
Smith+Nephew Honing U.S. Knee Offerings
The company’s sustained improvement in joint replacement comes amid a commercial shift and portfolio rationalization for knee replacement implants. The commercial organization is refocusing its efforts on higher-volume accounts. The company also plans to narrow down to two product families, LEGION and JOURNEY.
Stryker Bullish on Orthopedic Market Health
Stryker remains bullish on the market environment despite ongoing trade and geopolitical uncertainty, citing healthy procedure volumes, adoption of robotic-assisted surgery, stable pricing, favorable demographic shifts and ongoing ASC acceleration.
You are out of free articles for this month
Subscribe as a Guest for $0 and unlock a total of 5 articles per month.
You are out of five articles for this month
Subscribe as an Executive Member for access to unlimited articles, THE ORTHOPAEDIC INDUSTRY ANNUAL REPORT and more.
ME
Mike Evers is a Senior Market Analyst and writer with over 15 years of experience in the medical industry, spanning cardiac rhythm management, ER coding and billing, and orthopedics. He joined ORTHOWORLD in 2018, where he provides market analysis and editorial coverage.
